1

2 Executive dysfunction following SARS-CoV-2 infection: A cross-sectional

3 examination in a population-representative sample

- Peter A. Hall PhD^{1,2*}, Gang Meng PhD², Anna Hudson MSc¹, Mohammad N. Sakib MBBS¹, Sara C.
 Hitchman PhD³, James McKillop PhD⁴, Warren K. Bickel PhD⁵, and Geoffrey T. Fong PhD^{1,2,4*}
- 6
- 7 ¹ School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada
- 8 ² Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada
- ³ Department of Communication and Media Research, University of Zurich, Zurich, Switzerland.
- ⁴ Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario,
- 11 Canada
- 12 ⁵ Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, Virginia, USA
- ^{6.} Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- 14
- 15 *Corresponding author information:
- 16 Peter A. Hall, Ph.D., School of Public Health Sciences, University of Waterloo, 200 University Avenue
- 17 West, Waterloo, Ontario, Canada, N2L 3G1.
- 18 Geoffrey T. Fong, Ph.D., Department of Psychology, University of Waterloo, 200 University Avenue West,
- 19 Waterloo, Ontario, Canada, N2L 3G1
- 20 E-mail: pahall@uwaterloo.ca
- 21 Phone: 519-888-4567 x48110 22

23 Abstract

24

25 **Background:** Prior studies have documented reliable associations between SARS-CoV-2 infection and

adverse cognitive impact in older adults. The current study sought to determine whether SARS-CoV-2
 infection and COVID-19 symptom severity are associated with cognitive dysfunction among young adults

- and middled-aged adults in the general population.
- 29 **Method:** The Canadian COVID-19 Experiences Project (CCEP) survey involves 1,958 adults with equal
- 30 representation of vaccinated and vaccine hesitant adults between the ages of 18 and 54 years. The
- sample comprised 1,958 adults with a mean age of 37 years (*SD*=10.4); 60.8% were female. The
- 32 primary outcome was symptoms of cognitive dysfunction assessed via an abbreviated form of the Barkley
- 33 Deficits in Executive Functioning Scale (BDEFS) and performance on a validated decision-making task.
- 34
- 35 **Results:** Young and middle-aged adults with a positive SARS-CoV-2 infection history reported a
- 36 significantly higher number of symptoms of executive dysfunction (M_{ad} =1.89, SE=0.08, Cl: 1.74, 2.04;
- n=175) than their non-infected counterparts ($M_{adi}=1.63$, SE=0.08, Cl. 1.47, 1.80; n=1,599; β=0.26,
- 38 *p*=.001). Among those infected, there was a dose-response relationship between COVID-19 symptom
- 39 severity and level of executive dysfunction, with moderate (β =0.23, *Cl*: 0.003-0.46) and very/extremely
- 40 severe (β = 0.69, *Cl*: 0.22-1.16) COVID-19 symptoms being associated with significantly greater
- 41 dysfunction, compared to asymptomatic. These effects remained reliable and of similar magnitude after
- 42 controlling for age, sex, vaccination status, income, and geographic region, and after removal of those
- 43 who had been intubated during hospitalization. Similar effects were found for the decision-making task.
- 44
- 45 Conclusions: Positive SARS-CoV-2 infection history and COVID-19 symptom severity are associated
 46 with executive dysfunction among young and middle-aged adults with no history of medically induced
- 47 coma. These findings are evident on self-reported and task-related indicators of cognitive function.
- 48
- 49 Key words: SARS-CoV-2; COVID-19; brain; cognition; executive function

50 Introduction

Cognitive dysfunction is one of the potential adverse consequences of SARS-CoV-2 51 infection, and this risk may extend well below the age margins for increased mortality 52 risk. It is understood that SARS-CoV-2 could impact the brain through a number of non-53 exclusive, indirect mechanisms including hypoxia, thrombosis, coagulopathy, cytokine 54 storm, and megakaryocyte invasion.¹⁻⁶ Studies of predominantly older, hospitalized 55 patients have revealed cognitive deficits in the areas of memory, spatial navigation, 56 attention, short-term memory, and executive function.⁵⁻⁷ Further, the cognitive 57 impairments following SARS-Cov-2 infection may persist after the acute phase of 58 infection,⁵ a phenomenon known as "long covid".^{8,9} 59

Several studies have reported reliable evidence of cognitive dysfunction among 60 those previously infected with SARS-CoV-2.7,10-13 However, some of these studies are 61 limited by non-representative samples and lack of comparison to non-infected controls 62 in the general population. Examination of a population-based sample including 63 asymptomatic and minimally symptomatic individuals, coupled with a control sample of 64 non-infected individuals from the same population facilitates quantification of the 65 reliability and magnitude of SARS-CoV-2 infection impacts on cognition, if they do 66 indeed exist. Beyond the above, relatively little is known about the extent to which 67 cognitive deficits are predicted by age or sex, as demographic moderators. The extent 68 to which SARS-CoV-2 adversely impacts cognitive function among younger and middle-69 aged adults is relatively unknown. Of particular interest are the executive functions, 70 which are especially susceptible to environmental and systemic insult. 71

Executive functions are partially supported by the lateral prefrontal cortex, as well as 72 the medial orbitofrontal cortex (mOFC). The mOFC is of particular interest, being the 73 brain subregion most anatomically close to the hypothesized point of SARS-CoV-2 74 neuroinvasion. Decision-making processes supported by the OFC can be best 75 assessed using decision-making paradigms with heavy temporal and evaluative 76 demands, such as a delay discounting task.^{14–17} Delay discounting is a neurobehavioral 77 process reflecting the extent to which future rewards are devalued based on their delay 78 in time¹⁸ and summarized relative balance between the prefrontal cortices and the 79 limbic systems.¹⁴ Greater delay discounting is reflected in the tendency to choose a 80 lower value option that is immediately available over a higher value option that is 81 82 delayed in time.

Prior studies have shown that damage to the mOFC is associated with increased 83 delay discounting.^{16,17} Impulsive choice of rewards is mediated by dopaminergic activity 84 within the mOFC,¹⁹ in contrast with choices to avoid punishment, which are mediated by 85 the lateral OFC.²⁰ The most anterior aspect of the mOFC has further been proposed as 86 the subregion most clearly involved in processing of abstract rewards (e.g., money), in 87 contrast with the posterior mOFC, which is involved in computation of basic rewards 88 (e.g., food, physical pleasure).²⁰ Importantly, the anterior mOFC is located immediately 89 superior to the olfactory bulb and nasal mucous membrane, the primary hypothesized 90

Executive dysfunction 3

sites for SARS-CoV-2 neuroinvasion, and the presumed source of symptoms of
 anosmia and ageusia reported by some infected individuals.²¹ This may be a partial

93 explanation for the diverse neuropsychiatric symptoms²² displayed by many patients

94 with severe COVID-19.

95 The current study reports findings from a large national survey of adults in the general population, who reported cognitive status, SARS-CoV-2 infection history, and 96 COVID-19 symptom severity. It was hypothesized based on prior research^{7,10–13} that 97 positive SARS-CoV-2 infection history would be associated with greater self-reported 98 99 cognitive dysfunction, and that severity of COVID-19 symptoms would be positively correlated with severity of cognitive dysfunction, in a dose response manner. Finally, 100 101 based on the proximity of the mOFC to the hypothesized site of neuroinvasion of SARS-CoV-2, it was expected that deficits would be evident on a delay discounting task. 102

103

104 **1. Methods**

105 Participants

Participants were recruited as part of the Canadian COVID-19 Experiences Project 106 (CCEP)²³, a multi-study project which includes a national cohort survey of 1,958 adults 107 aged 18 to 54. One research objective was to examine differences between fully 108 vaccinated and vaccine-hesitant individuals on a broad set of demographic. 109 110 psychosocial, and experiential variables. Thus, the cohort was recruited to have an equal proportion of fully vaccinated and vaccine-hesitant Canadians: 50.2% received 111 two vaccine doses, 43.3% had received no doses, and 6.5% received one vaccine 112 113 dose, but were not intending to receive a second. The mean age was 37 (SD=10.4) and 114 60.8% were female.

115 **Procedure**

The survey was conducted from 28 September to 21 October 2021, when the 116 predominant SARS-CoV-2 variant in Canada was Delta (4 weeks prior to the 117 appearance of Omicron).²⁴ Participants were contacted by email with an invitation to 118 participate in the survey. A link to the survey was provided for eligible participants, and 119 120 all measures were completed online following provision of informed consent. A guota target of equal number of vaccinated and vaccine hesitant was applied to obtain a 121 balanced sample with respect to both vaccinated and vaccine-hesitant populations. 122 123 Within each quota target, the sample was recruited from ten Canadian provinces 124 through an online survey panel (Leger Opinion, the largest nationally representative probability-based panel in Canada). The survey firm and University of Waterloo 125 126 monitored survey response in the sample of each quota to achieve the final representative sample. This study was reviewed and received ethics clearance from the 127 institutional research ethics board of the University of Waterloo. 128

Executive dysfunction 4

129 Measures

Executive dysfunction. Symptoms of executive dysfunction were assessed using four "self-restraint" subscale items from the Deficits in Executive Functioning Scale, short form (BDEFS-SF)²⁵. Respondents were asked how often they have experienced each the four problems during the past 6 months, including "I am unable to inhibit my reactions or responses to events or to other people", "I make impulsive comments to others", "I am likely to do things without considering the consequences for doing them",

- and "I act without thinking". Responses were indicated on a numerical scale where 1= never or rarely, 2=sometimes, 3=often, and 4=very often. Cronbach's alpha for the 4
- 137 items was 0.89, indicating acceptable reliability. The four executive dysfunction items
- 139 were averaged for this analysis to create a composite executive dysfunction measure.
- 140 Delay discounting. To assess delay discounting, participants competed a validated 5-
- 141 trial delay discounting task wherein they were presented with a series of hypothetical
- 142 choices between a smaller monetary amount (\$500) immediately or a larger amount
- 143 (\$1,000) at various time delays (e.g.,1 month, 3 months).²⁶ Delay discounting was
- calculated as a *k* value, reflecting the steepness of a hyperbolic devaluation of delayed
- rewards; higher values of *k* indicate more impulsive choice.
- 146 SARS-CoV-2 infection status: Infection status was assessed using the question "What
- 147 best describes YOUR experience with [SARS-CoV-2] infection?" where 1= I have NOT
- been infected, 2 =I have been infected, and 3= not stated.
- 149 *Symptom severity:* COVID-19 symptom severity was assessed among those who have
- been infected by SARS-CoV-2 using two questions. (1) "How do you know that you
- 151 HAVE BEEN infected with [SARS-CoV-2]?" responses were given the answers of 1=
- had symptoms but did not get tested, 2= had symptoms and tested positive, and 3 =
- had no symptoms but tested positive. (2) "How severe was your [SARS-CoV-2] illness?"
- 154 The five-point response scale was 1=not at all severe, 2=slightly severe, 3=moderately
- severe, 4=very severe, 5=extremely severe. Those reporting "had no symptoms but
- 156 tested positive" were incorporated into the second question as 1=not at all severe.

157 Statistical analysis

- 158 Samples were post-stratified by geographic/language regions: Alberta, British Columbia,
- 159 Manitoba + Saskatchewan, Ontario, Quebec English, and Quebec French, and Atlantic
- 160 provinces (Nova Scotia, New Brunswick, Prince Edward Island, Newfoundland and
- Labrador). For each of the vaccinated and vaccine hesitant group separately, sampling
- weights were computed using a raking procedure and calibrated to target marginal joint
- 163 population distributions of the geographic/language regions, and the gender and age
- 164 group combinations, based on population figures in the 2016 Canadian census data and 165 the disposition code in the sample, thus allowing generalization to the Canadian
- 166 population. Survey linear regression models incorporating survey strata and weights
- 167 were applied to estimate composite executive dysfunction scores and their associations
- 168 with SARS-CoV-2 infection status and COVID-19 symptom severity. Regression models

Executive dysfunction 5

controlled for respondents' gender and age groups (18-24, 25-39 and 40-54). All models
were conducted in SAS with SUDAAN V11. All confidence intervals (CI) and statistical
significance were assessed at the 95% confidence level.

- 172
- 173 174

2. Results

Baseline characteristics of the sample are presented in Table 1. The majority of the participants were female (60%) and from the 25-39 (40%) or 40-54 (43%) age groups. 84% of participants reported that they had not been infected; those who reported having been infected reported symptoms to be "not at all severe" (3%), "slightly severe" (2.4%), "moderately severe" (2.7%), with relatively few experiencing "very/extremely severe" symptoms (1%). The two cognitive measures were positively correlated (*r*=0.17, *p*<.001).

182 Self-reported Executive Dysfunction

183 Those who reported a prior SARS-CoV-2 infection reported a significantly higher

number of symptoms of executive dysfunction (M_{adj} =1.89, SE=0.08, CI: 1.74, 2.04;

n=175) than their non-infected counterparts (M_{adj} =1.63, SE=0.08, Cl: 1.47, 1.80;

186 $n=1,599; \beta=0.26, p=.001$). Men were likely to experience more executive dysfunction

than women (β = 0.15, *p*<.001); younger adults (25-39 years) were more likely to

experience executive dysfunction than middle aged adults (40-54 years; β = 0.30, *p*<.001).

190 Among those who were infected, there was a dose-response relationship between COVID-19 symptom severity and executive dysfunction. Participants who reported 191 192 "moderately severe" ($M_{adi} = 1.85, 95\%$ C/ 1.63 – 2.08) and "very" or "extremely severe" $(M_{adi} = 2.32, 95\% CI 1.85 - 2.78)$ COVID-19 symptoms were significantly more likely to 193 have higher levels of executive dysfunction compared to non-infected individuals (M_{adi} = 194 1.62, 95% CI 1.58 – 1.66) (Table 2). A dose-response relationship between COVID-19 195 symptom severity and cognitive dysfunction was evident, those with moderate (β =0.23, 196 197 *Cl*: 0.003-0.46) and very/extremely severe (β = 0.69, *Cl*: 0.22-1.16) COVID-19 symptoms being associated with significantly greater degrees of executive dysfunction, 198 compared to those not infected and those with asymptomatic infections (Figure 2). 199 200 Removing the those who reported having been intubated (n=5) or hospitalized without intubation (*n*=5) did not change the findings. Likewise, following further adjustment for 201 vaccination status, income, and geographical region, those in the very/extremely severe 202 symptom categories continued to report significantly greater symptoms of executive 203 dysfunction than the non-infected reference group (β =0.71, 95% Cl 0.22 - 1.19, p=.004). 204

205 Delay Discounting Task Performance

Participants infected with SARS-CoV-2 displayed significantly higher delay discounting rates (k = 1.22, SE=0.48, Cl: 0.27, 2.16) than non-infected participants (k=0.37, SE=0.08, Cl: 0.21, 0.52; $\beta=.31$, p=.017; Table 3). With respect to dose-

Executive dysfunction 6

209 response effects of symptom severity, among infected individuals, those reporting "very

- severe" COVID-19 symptoms demonstrated significantly higher delay discounting rates
- than those reporting no infection history, with the remaining severity categories falling
- between these two values. Discount curves for infected versus non-infected, and among severity levels ranging from asymptomatic and very severe are presented in
- Figure 1 panel b.
- In general, males had marginally steeper discount rates than females (β =-.10,
- p=.066), and individuals reporting high incomes had significantly lower discounting rates
- than individuals reporting low income (β =-.30, *p*<.001). No significant age differences in
- k values were observed (see supplementary materials). No two-way interactions were
- observed between sex and infection status predicting delay discounting were observed (Wald F=0.09, p=0.91), or between age and infection status predicting delay discounting
- (Wald F=0.90, p=0.46). Likewise, the three-way interaction term between sex, age and
- infection status in predicting delay discounting was non-significant (Wald F=1.37,
- 223 *p*=0.22).

224 Sensitivity Analyses

Further adjustment for education and geographical region (i.e., province) had no 225 226 overall effect on the findings. In education and province-adjusted models, those reporting a SARS-CoV-2 infection continued to show a significantly greater degree of 227 delay discounting than those non-infected (β =-0.32, *CI*:-0.57,-0.06, *p*=.014). Also similar 228 to earlier analyses, those in the "very severe" COVID-19 symptom severity category 229 showed greater discounting than those in the non-infected group (β =1.28, *Cl*: 0.35,2.21, 230 p=.007). Likewise, removal of 5 cases reporting being placed on mechanical ventilator 231 did not change the effects of SARS-CoV-2 infection status (β =.23, Cl: 0.01,0.45, 232 p=.043) or COVID-19 symptom severity ($\beta = .95$, Cl: 0.20, 1.71, p=.014) on delay 233 discounting rate. Finally, when limiting the "infected" group to only those whom reported 234 having their infection confirmed by a positive PCR test, the effect of SARS-CoV-2 235 236 infection remained significant, and somewhat stronger in magnitude (β =.40; CI: 0.07, 0.72, *p*=.016). 237

238

3. Discussion

In this population-representative cohort of community-dwelling adults, those with a 240 positive history of SARS-CoV-2 infection reported more symptoms of cognitive 241 dysfunction than those with no such history. This effect was evident on both self-242 reported symptoms of executive dysfunction and on a validated decision-making task. A 243 dose-response relationship between COVID-19 symptom severity and magnitude of 244 cognitive dysfunction was evident such that increasing infection severity was associated 245 with greater symptoms of cognitive dysfunction for both self-reported symptoms and 246 task performance. Importantly, reliable effects of positive SARS-CoV-2 infection history 247 and COVID-19 symptom severity on cognitive dysfunction were evident—on both 248

Executive dysfunction 7

249 measures—even in this sample of individuals not typically subject to age-related cognitive decline (ages 18 to 54) and not exposed to medically induced coma via 250 251 hospital-based treatment for severe COVID-19. Our findings were similar to a prior report of executive dysfunction as correlated with COVID-19 symptom severity in a 252 large population sample¹³, but extend them to include self-reported symptoms of 253 interpersonal significance, and a standardized decision making paradigm previously 254 linked to the site of hypothesized neuroinvasion of the SARS-CoV-2 virus (the mOFC; 255 Figure 1 panel A). 256

There are several hypothesized mechanisms by which SARS-CoV-2 infection may 257 produce cognitive dysfunction, including encephalitis, coagulopathy, cytokine storm, 258 hypoxia, and megakaryocyte invasion.⁴⁻⁶ The current investigation cannot distinguish 259 among these neurophysiological mechanisms, or others that may yet be identified. The 260 current findings do not preclude the possibility that symptoms of cognitive dysfunction 261 are influenced by reporting biases among those who are continuing to experience 262 emotional distress following the measurement period. Given that the effects of negative 263 mood on symptom reporting is causally established,^{27,28} and given that mood impacts of 264 the COVID-19 pandemic are well-documented,²⁹⁻³³ this possibility cannot be definitively 265 excluded. However, at least one prior population-based study has found similar dose-266 response effects using performance-based measures of cognitive function (i.e., 267 cognitive tasks rather than reported symptoms).⁷ It is further noteworthy that the same 268 patterns were evident on our decision-making task. 269

It is not clear why there appeared to be a stronger link between SARS-CoV-2 270 271 infection and cognitive dysfunction in younger adults as compared with middle-aged adults. It is possible that such deficits were more salient to younger adults, given that a 272 higher proportion would be in educational programs wherein lapses in attention and 273 concentration may have been more impactful. In either case, it is not clear how 274 275 consequential symptoms of cognitive dysfunction would be expected to be, even if reliable across studies. It is not uncommon for other types of viral infections to cause 276 symptoms of cognitive dysfunction, including the seasonal flu, herpes, MERS, Zika and 277 Varicella (chickenpox).^{34–38} Documenting the stability and functional impact of any 278 SARS-CoV-2 infection impairments in cognition will be important. However, in the 279 meantime, reductions in unnecessary exposure to SARS-CoV-2 infection may be an 280 important public health strategy even for young and middle aged adults, despite the 281 282 limited mortality risk.

Finally, given that the predominant SARS-CoV-2 variant during the time of the survey was Delta, the findings are applicable only to the Delta and earlier variants. Moreover, the retrospective nature of the study does not allow us to determine with confidence which infections were attributable to Delta versus earlier variants. We also cannot conclude that the same associations would be observed with the Omicron variant, in particular because of the lower COVID-19 symptom severity apparent with Omicron in comparison with earlier variants, at least based on early data.^{39–41} In the

current (pre-Omicron) sample, we found that only moderate and higher COVID-19

291 symptom severities were associated with significantly elevated symptoms of executive

dysfunction. Further analyses of follow-up waves of the CCEP data will enable

examination of the relative impact of the Omicron variant on symptoms of executivedysfunction.

295 Strengths and Limitations

There are several strengths of the current study. One strength is the use of a large 296 297 population-representative sample, consisting of infected individuals of a wide range of 298 disease symptom severities—ranging from asymptomatic to hospitalized—as well as 299 non-infected controls. Another strength is the use of a validated measure of subjective 300 symptomology assessing everyday function rather than more sensitive but less 301 ecologically valid performance-based measures. Finally, the finding of similar effects on 302 a decision-making task performance increases confidence that the findings were not a 303 function of self-report methodology alone. In terms of limitations, by virtue of the survey format, it was not possible to validate the infection status of individuals by testing. This 304 305 may lead to under- or over-estimation of effect size and statistical significance of tests, 306 vis-a-vis misreporting of infection status. This is a limitation of many survey studies of COVID-19 and cognitive dysfunction, however. Finally, the cross-sectional design limits 307 our ability to draw causal inferences. 308

Future studies should examine the longevity of cognitive dysfunction symptoms over time, as well as the extent to which the dose-response and age gradients observed here are replicable across samples. Finally, additional studies examining neurological impacts at the level of the brain itself will be required, using functional brain imaging paradigms to quantify structural and functional impacts of SARS-CoV-2 infection. In particular studies are needed that follow individuals forward from the point of infection to examine changes over time, in a prospective manner.

316 Conclusions

317 In summary, the current study used a population-representative sample consisting of a balanced proportion of vaccinated and unvaccinated individuals to estimate the 318 319 association between SARS-CoV-2 infection and symptoms of cognitive dysfunction. 320 Findings indicated that individuals previously infected with SARS-CoV-2 reported significantly greater symptoms of cognitive dysfunction than non-infected individuals. 321 322 Further, among those reporting a positive infection history, a dose-response relationship between COVID-19 symptom severity and cognitive dysfunction was evident, such that 323 those with moderate to severe symptoms were more likely to experience symptoms of 324 cognitive dysfunction. The above pattern was evident for both self-reported symptoms 325 of cognitive dysfunction and performance on a decision-making task. Taken together 326 with findings from other studies, cognitive dysfunction appears to be a correlated of 327 SARS-CoV-2 infection, particularly among those with at least moderate COVID-19 328 symptom severity. If such cognitive effects are long-lasting, this may be one piece of 329

Executive dysfunction 9

- 330 evidence in support of public health strategies that eliminate exposure to SARS-CoV-2
- infection, even for young adults and those below the typical high-risk age threshold for
- mortality.
- 333

Research ethics statement

- This study protocol was reviewed by and received approval from the University of Waterloo Office of Research Ethics.
- 337

338 Funding statement

- 339 Funding for this study was provided by a grant from the Canadian Institutes of Health
- Research (GA3-177733) to P. Hall (PI), G. Fong (co-PI) and S. Hitchman (co-I).

341

342 Data Availability Statement

343 Data will be available upon reasonable request to either of the corresponding authors.

344

345 **Conflicts of Interests**

346 The authors declare no conflicts of interest.

347

348 Acknowledgements

We thank Anne C.K. Quah and Thomas Agar for their assistance with survey design and management.

351

352 Figure 1 Legend

353 Conceptual diagram (A) and delay discounting curves for non-infected and ranges of 354 COVID-19 symptom severity from asymptomatic to "very severe" (B).

355

356 Figure 2 Legend

- 357 Effects of SARS-CoV-2 infection status and COVID-19 symptom severity on BDEFS
- 358 scores; BDEFS=Barkley Deficits in Executive Functioning Scale.

Executive dysfunction 10

360	able 1:	Sample	characteristics.
-----	---------	--------	------------------

Variables	n	%	Executive function (unadjusted) Mean, 95% <i>Cl</i>	Executive function (adjusted) Mean, 95% <i>Cl</i>
Gender				
Male	747	39.27	-	-
Female	1155	60.73	-	-
Age Group				
18-24	313	16.46	-	-
25-39	769	40.43	-	-
40-54	820	43.11	-	-
Infection Status				
Not infected	1599	84.07	1.62 (1.58, 1.66)	1.62 (1.58, 1.66)
Infected: Not at all severe	57	3.00	1.72 (1.52, 1.93)	1.73 (1.54, 1.91)
Infected: Slightly severe	46	2.42	1.78 (1.44, 2.11)	1.75 (1.45, 2.05)
Infected: Moderately			1.83 (1.60, 2.06)	1.85 (1.63, 2.08)
severe	51	2.68		
Infected: Very/extremely			2.29 (1.82, 2.76)	2.32 (1.85, 2.78)
severe	21	1.10		
Not stated	128	6.73	1.64 (1.46, 1.81)	1.63 (1.47, 1.80)

Note: Executive dysfunction mean is the average of the four BDEFS items. Participants who had no COVID-19 symptoms, but tested positive for SARS-CoV-2, were classified as "not at all severe". The adjusted parameters are adjusted by sex and group. Table 1 includes the sample used in the current analysis (N = 1,902).

365

Table 2: Associations between SARS-CoV-2 infection status, COVID-19 symptom severity and BDEFS scores.

Variables	Beta (95% <i>Cl</i>)	p
Gender		
Male	0.15 (0.07, 0.22)	<0.001
Female	Ref	Ref
Age Group		
18-24	0.30 (0.19, 0.41)	<0.001
25-39	0.06 (-0.02, 0.14)	0.138
40-54	Ref	Ref
COVID-19 Infection Status		
Not infected	Ref	Ref
Infected: Not at all severe	0.10 (-0.09, 0.29)	0.284
Infected: Slightly severe	0.13 (-0.17, 0.42)	0.406
Infected: Moderately severe	0.23 (0.00, 0.46)	0.047
Infected: Very/Extremely severe	0.69 (0.22, 1.16)	0.004
Not stated	0.01 (-0.16, 0.18)	0.903

369

371 Table 3: Associations between SARS-CoV-2 infection status, COVID-19 symptom

372 severity and delay discounting.

Variables	Beta	р
	Infection Status	
COVID-19 infection status		
Infected	0.31 (0.06, 0.56)	0.017
Not infected	Ref	Ref
Not stated	-0.01 (-0.22, 0.20)	0.91
	Symptom Severity	/
Gender		
Male	-0.10 (-0.20, 0.01)	0.066
Female	Ref	Ref
Age group		
18-24	-0.04 (-0.18, 0.11)	0.618
25-39	0.01 (-0.11, 0.13)	0.893
40-54	Ref	Ref
Income	- <i>i</i>	- (
Low	Ref	Ref
Moderate	0.02 (-0.17, 0.21)	0.838
High	-0.30 (-0.45, -0.16)	< 0.001
No answer	-0.34 (-0.57, -0.12)	0.002
COVID-19 Infection status	D-f	Def
Not infected		Ref
Infected: Asymptomatic	-0.01(-0.29, 0.27)	0.934
Infected: Slightly severe	0.24 (-0.09, 0.57)	0.147
severe	0.34 (-0.11, 0.79)	0.141
Infected: Very severe	1.26 (0.31, 2.21)	0.009
Not stated	-0.01	0.92

373

Executive dysfunction 13

375 Author Contributions

376

377 PH, GF, and SH conceived the study, planned and oversaw the statistical analyses, and

wrote the final draft. GM planned and completed all statistical analyses and contributed

to the writing of the final draft. MNS, AH, JM, and WB contributed to the writing of the

380 final draft.

382 Ref	erences

- 383
- Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. JAMA
 Psychiatry. 2021;78(6):682. doi:10.1001/jamapsychiatry.2021.0500
- Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients
 With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683 690. doi:10.1001/jamaneurol.2020.1127
- McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. *Circ Res.* 2020;127(4):571-587. doi:10.1161/CIRCRESAHA.120.317447
- Nauen DW, Hooper JE, Stewart CM, Solomon IH. Assessing Brain Capillaries in Coronavirus Disease 2019. *JAMA Neurol.* 2021;78(6):760-762. doi:10.1001/jamaneurol.2021.0225
- Ritchie K, Chan D. The emergence of cognitive COVID. *World Psychiatry*.
 2021;20(1):52-53. doi:10.1002/wps.20837
- 397 6. Solomon T. Neurological infection with SARS-CoV-2 the story so far. *Nat Rev* 398 *Neurol.* 2021;17(2):65-66. doi:10.1038/s41582-020-00453-w
- Jaywant A, Vanderlind WM, Alexopoulos GS, Fridman CB, Perlis RH, Gunning FM.
 Frequency and profile of objective cognitive deficits in hospitalized patients
 recovering from COVID-19. *Neuropsychopharmacology*. 2021;46(13):2235-2240.
 doi:10.1038/s41386-021-00978-8
- 403 8. Ladds E, Rushforth A, Wieringa S, et al. Persistent symptoms after Covid-19:
 404 qualitative study of 114 "long Covid" patients and draft quality principles for
 405 services. *BMC Health Serv Res.* 2020;20(1):1144. doi:10.1186/s12913-020-06001406 y
- 407 9. Rubin R. As Their Numbers Grow, COVID-19 "Long Haulers" Stump Experts.
 408 JAMA. 2020;324(14):1381-1383. doi:10.1001/jama.2020.17709
- Becker JH, Lin JJ, Doernberg M, et al. Assessment of Cognitive Function in
 Patients After COVID-19 Infection. *JAMA Netw Open*. 2021;4(10):e2130645.
 doi:10.1001/jamanetworkopen.2021.30645
- Liu YH, Wang YR, Wang QH, et al. Post-infection cognitive impairments in a cohort
 of elderly patients with COVID-19. *Mol Neurodegener*. 2021;16(1):48.
 doi:10.1186/s13024-021-00469-w
- Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following
 COVID-19 infection: Clinical predictors leading to neuropsychological impairment.
 Brain Behav Immun Health. 2020;9:100163. doi:10.1016/j.bbih.2020.100163

- Hampshire A, Trender W, Chamberlain SR, et al. Cognitive Deficits in People Who
 Have Recovered from COVID-19 Relative to Controls: An N=84,285 Online Study.;
 2020:2020.10.20.20215863. doi:10.1101/2020.10.20.20215863
- 421 14. McClure SM, Laibson DI, Loewenstein G, Cohen JD. Separate Neural Systems
 422 Value Immediate and Delayed Monetary Rewards. *Science*. 2004;306(5695):503 423 507. doi:10.1126/science.1100907
- Massar SAA, Libedinsky C, Weiyan C, Huettel SA, Chee MWL. Separate and
 overlapping brain areas encode subjective value during delay and effort
 discounting. *NeuroImage*. 2015;120:104-113.
 doi:10.1016/j.neuroimage.2015.06.080
- Peters J, D'Esposito M. Effects of Medial Orbitofrontal Cortex Lesions on SelfControl in Intertemporal Choice. *Curr Biol.* 2016;26(19):2625-2628.
 doi:10.1016/j.cub.2016.07.035
- 431 17. Sellitto M, Ciaramelli E, di Pellegrino G. Myopic Discounting of Future Rewards
 432 after Medial Orbitofrontal Damage in Humans. *J Neurosci.* 2010;30(49):16429 433 16436. doi:10.1523/JNEUROSCI.2516-10.2010
- Bickel WK, Marsch LA. Toward a behavioral economic understanding of drug
 dependence: delay discounting processes. *Addiction*. 2001;96(1):73-86.
 doi:10.1046/j.1360-0443.2001.961736.x
- 437
 437
 438
 438
 439
 439
 439
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
- Kringelbach ML, Rolls ET. The functional neuroanatomy of the human orbitofrontal
 cortex: evidence from neuroimaging and neuropsychology. *Prog Neurobiol.* 2004;72(5):341-372. doi:10.1016/j.pneurobio.2004.03.006
- Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common
 Findings in COVID-19 Patients. *The Laryngoscope*. 2020;130(7):1787-1787.
 doi:10.1002/lary.28692
- Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological
 and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective
 cohort study using electronic health records. *Lancet Psychiatry*. 2021;8(5):416-427.
 doi:10.1016/S2215-0366(21)00084-5
- 451 23. Hall P, Fong G, Hitchman S. The Canadian COVID-19 Experiences Survey: Study
 452 Protocol. medRxiv. Published online 2021.
- 453 24. Canada PHA of. COVID-19 daily epidemiology update. aem. Published April 19,
 454 2020. Accessed January 2, 2022. https://health-infobase.canada.ca/covid-

Executive dysfunction 16

- 455 **19/epidemiological-summary-covid-19-**
- 456 cases.html?stat=rate&measure=total_last14&map=pt
- 457 25. Barkley RA. Barkley Deficits in Executive Functioning Scale (BDEFS). Guilford
 458 Press; 2011.
- 459 26. Koffarnus MN, Bickel WK. A 5-trial adjusting delay discounting task: Accurate
 460 discount rates in less than one minute. *Exp Clin Psychopharmacol.*461 2014;22(3):222-228. doi:10.1037/a0035973
- 462 27. Howren MB, Suls J. The symptom perception hypothesis revised: Depression and
 463 anxiety play different roles in concurrent and retrospective physical symptom
 464 reporting. *J Pers Soc Psychol.* 20110110;100(1):182. doi:10.1037/a0021715
- 28. Reimers S, Maylor EA, Stewart N, Chater N. Associations between a one-shot
 delay discounting measure and age, income, education and real-world impulsive
 behavior. *Personal Individ Differ*. 2009;47(8):973-978.
 doi:10.1016/j.paid.2009.07.026
- 29. Czeisler MÉ, Lane RI, Petrosky E, et al. Mental Health, Substance Use, and
 Suicidal Ideation During the COVID-19 Pandemic United States, June 24–30,
 2020. *Morb Mortal Wkly Rep.* 2020;69(32):1049-1057.
 doi:10.15585/mmwr.mm6932a1
- 30. Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health
 in the general population: A systematic review. *J Affect Disord*. 2020;277:55-64.
 doi:10.1016/j.jad.2020.08.001
- 476 31. Duan L, Shao X, Wang Y, et al. An investigation of mental health status of children
 477 and adolescents in china during the outbreak of COVID-19. *J Affect Disord*.
 478 2020;275:112-118. doi:10.1016/j.jad.2020.06.029
- 32. Daly M, Sutin AR, Robinson E. Longitudinal changes in mental health and the
 COVID-19 pandemic: evidence from the UK Household Longitudinal Study. *Psychol Med.* Published online November 13, 2020:1-10.
 doi:10.1017/S0033291720004432
- 483 33. Hall PA, Sheeran P, Fong GT, et al. Biobehavioral Aspects of the COVID-19
 484 Pandemic: A Review. *Psychosom Med.* 2021;83(4):309-321.
 485 doi:10.1097/PSY.0000000000932
- 486 34. Goenka A, Michael BD, Ledger E, et al. Neurological Manifestations of Influenza
 487 Infection in Children and Adults: Results of a National British Surveillance Study.
 488 *Clin Infect Dis.* 2014;58(6):775-784. doi:10.1093/cid/cit922
- 489 35. Kim JE, Heo JH, Kim H ok, et al. Neurological Complications during Treatment of
 490 Middle East Respiratory Syndrome. *J Clin Neurol*. 2017;13(3):227.
 491 doi:10.3988/jcn.2017.13.3.227

- de Araújo TVB, Rodrigues LC, de Alencar Ximenes RA, et al. Association between
 Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary
 report of a case-control study. *Lancet Infect Dis.* 2016;16(12):1356-1363.
 doi:10.1016/S1473-3099(16)30318-8
- 496 37. Berger JR, Houff S. Neurological Complications of Herpes Simplex Virus Type 2
 497 Infection. *Arch Neurol.* 2008;65(5). doi:10.1001/archneur.65.5.596
- 498 38. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ.
 499 Neurologic Complications of the Reactivation of Varicella–Zoster Virus. *N Engl J* 500 *Med.* 2000;342(9):635-645. doi:10.1056/NEJM200003023420906
- S01 39. Christie B. Covid-19: Early studies give hope omicron is milder than other variants.
 BMJ. 2021;375:n3144. doi:10.1136/bmj.n3144
- 40. Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first
 global omicron variant covid-19 outbreak in a large hospital in tshwane, south
 africa. *Int J Infect Dis.* Published online December 2021:S120197122101256X.
 doi:10.1016/j.ijid.2021.12.357
- 507 41. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron
 508 variant of concern and vaccine effectiveness against symptomatic disease: national
 509 cohort with nested test negative design study in Scotland. Published online
 510 December 22, 2021. Accessed January 2, 2022.
- 511 https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-
- 512 concern-and-vaccine-effectiveness-





